Senzime (OM:SEZI) - Cotización, noticias y análisis

Resumen de acción SEZI

SEZI fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Recompensas

Cotiza un 46.7% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 73.58%

Análisis de riesgos

No tiene ingresos significativos (SEK36M)

No tiene una capitalización de mercado significativa (SEK711M)

Los accionistas han sido diluidos en el último año

Competidores de Senzime AB (publ)

Paxman

OM:PAX

kr680.6m

Integrum

OM:INTEG B

kr1.1b

ADDvise Group

OM:ADDV A

kr1.6b

Ortoma

OM:ORT B

kr361.2m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Senzime
Historical stock prices
Current Share Price	kr7.00
52 Week High	kr8.46
52 Week Low	kr2.61
Beta	0.53
1 Month Change	12.90%
3 Month Change	-12.72%
1 Year Change	35.40%
3 Year Change	-68.47%
5 Year Change	15.13%
Change since IPO	-18.60%

Noticias y actualizaciones recientes

Recent updates

Shareholders of Senzime (STO:SEZI) Must Be Delighted With Their 607% Total Return

Feb 16

We're Hopeful That Senzime (STO:SEZI) Will Use Its Cash Wisely

Jan 19

Are Insiders Buying Senzime AB (publ) (STO:SEZI) Stock?

Dec 23

What Kind Of Investors Own Most Of Senzime AB (publ) (STO:SEZI)?

Nov 26

Rentabilidad de los accionistas

	SEZI	SE Medical Equipment	Mercado SE
7D	18.2%	2.3%	0.1%
1Y	35.4%	-5.4%	11.2%

Rentabilidad vs. Industria: SEZI superó al sector Swedish Medical Equipment , que obtuvo un rendimiento del -8.9% el año pasado.

Rentabilidad vs. Mercado: SEZI superó al mercado Swedish, que obtuvo un rendimiento del 10.3% el año pasado.

Volatilidad de los precios

Is SEZI's price volatile compared to industry and market?
SEZI volatility
SEZI Average Weekly Movement	8.9%
Medical Equipment Industry Average Movement	7.6%
Market Average Movement	6.3%
10% most volatile stocks in SE Market	13.5%
10% least volatile stocks in SE Market	3.6%

Precio estable de las acciones: SEZI no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de SEZI (8%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1999	45	Philip Siberg	www.senzime.com

Senzime AB (publ), empresa de dispositivos médicos, desarrolla, fabrica y comercializa sistemas de monitorización de pacientes basados en algoritmos para aumentar la seguridad del paciente durante y después de la cirugía en Europa y Estados Unidos. Ofrece TetraGraph, un monitor cuantitativo de la transmisión neuromuscular, que ayuda a gestionar el bloqueo neuromuscular desde la inducción hasta la recuperación; y ExSpiron, un sistema de monitorización no invasivo que utiliza la impedancia bioeléctrica para medir la oposición del tejido a transportar una corriente eléctrica alterna. La empresa tiene un acuerdo estratégico de conectividad y licencia con Masimo para desarrollar, fabricar, comercializar y distribuir productos que puedan conectarse al sistema de monitorización de pacientes Masimo Root y al centro digital relacionado para la transmisión de datos a los diarios electrónicos de pacientes de los hospitales; un acuerdo de licencia con Fukuda Denshi Co. Ltd.

Resumen de fundamentos de Senzime AB (publ)

¿Cómo se comparan los beneficios e ingresos de Senzime con su capitalización de mercado?
Estadísticas fundamentales de SEZI
Capitalización bursátil	kr837.94m
Beneficios(TTM)	-kr134.15m
Ingresos (TTM)	kr35.75m

23.4x

Ratio precio-ventas (PS)

-6.2x

Ratio precio-beneficio (PE)

¿Está SEZI sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de SEZI
Ingresos	kr35.75m
Coste de los ingresos	kr27.42m
Beneficio bruto	kr8.34m
Otros gastos	kr142.49m
Beneficios	-kr134.15m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

May 07, 2024

Beneficios por acción (BPA)	-1.12
Margen bruto	23.32%
Margen de beneficio neto	-375.20%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado SEZI a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción SEZI

Recompensas

Análisis de riesgos

Competidores de Senzime AB (publ)

OM:PAX

kr680.6m

OM:INTEG B

kr1.1b

OM:ADDV A

kr1.6b

OM:ORT B

kr361.2m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Full year 2023 earnings: EPS and revenues miss analyst expectations

Senzime AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Senzime AB (publ) Announces Board Changes

Chief Financial Officer recently bought kr67k worth of stock

Recent updates

Full year 2023 earnings: EPS and revenues miss analyst expectations

Senzime AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Senzime AB (publ) Announces Board Changes

Chief Financial Officer recently bought kr67k worth of stock

Chief Financial Officer recently bought kr67k worth of stock

Senzime Announces New Clinical Study with the Tetragraph System Published in the British Journal of Anesthesia Open

Senzime AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Shareholder dilution

Senzime Launches Tetras Sensitive, the Market's First Sensor for Nemomuscular Monitoring of Patients with Sensitive Skin

New major risk - Financial position

Senzime AB (publ) Announces New Study Valued the Feasibility of TetraSens Pediatric Disposable Sensor

Senzime AB (publ) Presents Scientific Study at Euroanaesthesia 2023 and Validates New TetraGraph Electromyographic Detection Algorithm

Less than half of directors are independent

Senzime AB (Publ) Appoints Philip Siberg as Chief Executive Officer

First quarter 2023 earnings released: kr0.42 loss per share (vs kr0.33 loss in 1Q 2022)

Independent Chairman recently bought kr740k worth of stock

Senzime Receives Approval for Its Pediatric Sensor in Japan

Full year 2022 earnings released: kr1.99 loss per share (vs kr1.31 loss in FY 2021)

Senzime AB (publ) to Report Q1, 2023 Results on May 05, 2023

Senzime AB (publ) to Report Fiscal Year 2022 Results on Feb 01, 2023

Senzime Receives First Contract for TetraSens Pediatric in the US

Senzime's TetraGraph supported by new European clinical guidelines for patient monitoring

Third quarter 2022 earnings released: kr0.74 loss per share (vs kr0.31 loss in 3Q 2021)

Less than half of directors are independent

Senzime AB (publ) Provides Earnings Guidance for 2025

Third quarter 2022 earnings released: kr0.74 loss per share (vs kr0.31 loss in 3Q 2021)

Senzime AB (Publ) Announces Board Appointments

Senzime AB (publ) Receives FDA 510K-Clearance for New Disposable Sensor Intended for Monitoring of Children

Senzime AB (publ) Announces Launch of TetraGraph Xcom Interface to Electronic Medical Records

Consensus revenue estimates fall by 34%

Forecast breakeven date pushed back to 2024

Second quarter 2022 earnings released: kr0.63 loss per share (vs kr0.35 loss in 2Q 2021)

Senzime AB (publ) (OM:SEZI) entered into an agreement to acquire Respiratory Motion, Inc. for $44 million.

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to kr34.00

Less than half of directors are independent

Senzime AB (Publ) Applies for FDA Approval for A New Single-Use Sensor for Children

Will Senzime (STO:SEZI) Spend Its Cash Wisely?

Price target decreased to kr34.00

Full year 2021 earnings: EPS and revenues miss analyst expectations

Senzime Announces Anesthesia Patient Safety Foundation Recommends Use of A Quantitative Monitor Whenever A Neuromuscular Blocking Agent Is Administered

Senzime AB (Publ) Announces Japanese Study Confirms Tetragraph Monitor as a Better Indicator of Appropriate Reversal Dose of Sugammadex and Adequate Recovery of Neuromuscular Function Than Amg-Based Tof- Watch SX

Third quarter 2021 earnings released: kr0.31 loss per share (vs kr0.20 loss in 3Q 2020)

We Think Senzime (STO:SEZI) Can Afford To Drive Business Growth

Second quarter 2021 earnings released: kr0.35 loss per share (vs kr0.23 loss in 2Q 2020)

Companies Like Senzime (STO:SEZI) Are In A Position To Invest In Growth

First quarter 2021 earnings released: kr0.27 loss per share (vs kr0.17 loss in 1Q 2020)

How Much Of Senzime AB (publ) (STO:SEZI) Do Insiders Own?

Senzime AB (publ) Appoints Eva Walde as New Member of the Board of Directors

Full year 2020 earnings released: kr0.84 loss per share (vs kr0.68 loss in FY 2019)

Senzime AB (publ) to Report Q3, 2021 Results on Nov 12, 2021

New 90-day low: kr21.50

Shareholders of Senzime (STO:SEZI) Must Be Delighted With Their 607% Total Return

We're Hopeful That Senzime (STO:SEZI) Will Use Its Cash Wisely

New 90-day high: kr25.80

Senzime AB (publ) Gets US Patent for OnZurf Probe